DNA Damage Repair System and Antineoplastic Agents in Lung Cancer.
10.3779/j.issn.1009-3419.2022.101.24
- Author:
Linlin ZHANG
1
;
Fanlu MENG
1
;
Diansheng ZHONG
1
Author Information
1. Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Review
- Keywords:
Antineoplastic agents;
DNA damage;
DNA repair;
Lung neoplasms
- MeSH:
Antineoplastic Agents/therapeutic use*;
DNA Damage;
DNA Repair;
Humans;
Lung Neoplasms/genetics*;
Neoplasms/drug therapy*
- From:
Chinese Journal of Lung Cancer
2022;25(6):434-442
- CountryChina
- Language:Chinese
-
Abstract:
DNA damage repair (DDR) system plays an important role in maintaining of genomic stability. Accumulation of DNA lesions or deficiency of DDR system could drive tumorigenesis as well as promote tumor progression; meanwhile, they could also provide therapeutic opportunities and targets. Of all the antineoplastic agents of lung cancers, many of them targeted or were associated with DNA damage and repair pathways, such as chemotherapies and antibody-drug conjugates which were designed directly causing DNA damages, targeted drugs inhibiting DNA repair pathways, and immune-checkpoint inhibitors. In this review, we described the role of DNA damage and repair pathways in antitumor activity of the above agents, as well as summarized the application and clinical investigations of these antineoplastic agents in lung cancers, in order to provide more information for exploring precision and effective strategies for the treatment of lung cancer based on the mechanism of DNA damage and repair.
.
